Small molecules targeting the NMDA receptor complex as drugs for neuropathic pain.
Pain is a complex disease that usually remains poorly treated or undertreated, especially the neuropathic pain caused by injury to the peripheral or central nervous system. Antagonists of the NMDA receptor complex have emerged as potential drugs for pain management. A strong case is being raised for non-competitive or uncompetitive antagonists with low-to-moderate affinity and fast on/offset kinetics as drugs with good therapeutic profiles, because of their reduced side effects.
Planells-Cases
Rosa
R
Instituto de Biología Molecular y Celular, Universidad Miguel Hernández, Alicante, Spain.
Pérez-Payá
Enrique
E
Messeguer
Angel
A
Carreño
Cristina
C
Ferrer-Montiel
Antonio
A
D000818:Animals; D001667:Binding, Competitive / Q000187:drug effects; D016503:Drug Delivery Systems; D018690:Excitatory Amino Acid Agonists / Q000494:pharmacology / Q000627:therapeutic use; D018691:Excitatory Amino Acid Antagonists / Q000494:pharmacology / Q000627:therapeutic use; D006801:Humans; D010146:Pain / Q000188:drug therapy* / Q000503:physiopathology; D010523:Peripheral Nervous System Diseases / Q000188:drug therapy* / Q000503:physiopathology; D018009:Receptors, Glycine / Q000187:drug effects; D016194:Receptors, N-Methyl-D-Aspartate / Q000819:agonists / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects
D018690:Excitatory Amino Acid Agonists; D018691:Excitatory Amino Acid Antagonists; D018009:Receptors, Glycine; D016194:Receptors, N-Methyl-D-Aspartate